RVX.TO - Resverlogix Corp.

Toronto - Toronto Delayed Price. Currency in CAD
1.6100
+0.2100 (+15.00%)
As of 9:52AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.4000
Open1.4400
Bid1.6000 x 0
Ask1.6100 x 0
Day's Range1.4200 - 1.7800
52 Week Range0.3500 - 4.9400
Volume123,332
Avg. Volume184,303
Market Cap336.738M
Beta (3Y Monthly)0.13
PE Ratio (TTM)N/A
EPS (TTM)-0.5620
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
  • GlobeNewswire

    Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) announces that BETonMACE did not meet the primary endpoint – reduction in major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction and stroke – added to standard of care in high-risk patients with type 2 diabetes, recent acute coronary syndrome, and low HDL cholesterol. Apabetalone demonstrated tolerability and safety.

  • GlobeNewswire

    Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) today announces that it has issued a 10% secured convertible debenture in the principal amount of US$12 million (the “Debenture”) to a wholly-owned subsidiary of ORI Star Fund LP (“ORI” or the “Fund”). The Debenture bears interest at a rate of 10% per annum and matures on September 26, 2020. The Fund may elect to convert the Debenture into common shares of the Company at a conversion price equal to the lesser of CAD$2.54 per share and the 5-day volume weighted average trading price of the common shares on the date of conversion.

  • GlobeNewswire

    Resverlogix to Host BETonMACE Webcast and Conference Call

    CALGARY, Alberta, Sept. 26, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that, in connection with BETonMACE topline results, expected.

  • CNW Group

    Toronto Stock Exchange Introduces the TSX30

    Toronto Stock Exchange Introduces the TSX30

  • GlobeNewswire

    Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019

    CALGARY, Alberta, Sept. 23, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today the Late Breaking Science submission, regarding the primary.

  • GlobeNewswire

    Resverlogix Provides Update on BETonMACE Phase 3 Trial

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) announced today that, following the completion of final patient safety visits (as reported by the Company on July 8, 2019), the resolution of all outstanding queries is expected within a matter of days, leading to database lock. Furthermore, it is projected that the number of narrowly-defined Major Adverse Cardiovascular Events (“MACE”) – defined as a single composite endpoint of cardiovascular death or non-fatal myocardial infarction or stroke – to be used in the primary data analysis, is now estimated to be greater than 275 – compared to the initial calculation of 250 events in the trial’s protocol.

  • GlobeNewswire

    Resverlogix Announces Annual and Special Meeting of Shareholders

    CALGARY, Alberta, Aug. 22, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today that its Annual and Special Meeting of Shareholders (the.

  • GlobeNewswire

    Zenith Announces Annual and Special Meeting of Shareholders

    CALGARY, Alberta, Aug. 22, 2019 -- Zenith Capital Corp. (“Zenith”) announced today that its Annual and Special Meeting of Shareholders (the “Meeting”) is to be held Thursday,.

  • GlobeNewswire

    Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019

    CALGARY, Alberta, Aug. 14, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announces today that it will present at ESC Congress 2019, held this year in.

  • GlobeNewswire

    Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

    Zenith Capital Corp. (“Zenith”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics” or the “Company”), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara BioPharma Co., Ltd. (“Newsoara”) for the Company’s lead compound, ZEN-3694, in China, Hong Kong, Taiwan, and Macau (the “Territories”). Under the terms of the agreement, Newsoara will have the rights to develop, market, and distribute ZEN-3694 for all indications in the Territories.

  • GlobeNewswire

    Resverlogix Announces Loan Reduction and Extension

    CALGARY, Alberta, Aug. 02, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has entered into an amending agreement with Third Eye.

  • GlobeNewswire

    Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) announced today the recent publication of an article titled: “Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism” in Clinical Epigenetics, a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment.

  • GlobeNewswire

    Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits

    CALGARY, Alberta, July 08, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the.

  • GlobeNewswire

    Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

    Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the first patient in a Phase 1b/2 clinical trial undertaken in collaboration with Pfizer Inc. (“Pfizer”). The trial will evaluate the combination, safety and efficacy of the Company’s ZEN-3694, a novel and differentiated bromodomain and extra-terminal domain inhibitor (“BETi”), and Pfizer’s talazoparib, a poly ADP ribose polymerase inhibitor (“PARPi”), in patients with locally advanced or metastatic triple negative breast cancer without germline BRCA1/2 mutations. Preclinical data indicate that combining talazoparib with ZEN-3694 is a rational combination to test in patients that are proficient in homologous DNA repair.

  • GlobeNewswire

    Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) is pleased to announce today that all patients active in BETonMACE, the Company’s event-based, phase 3 registration trial, recently completed their last study visits on treatment. Once safety visits have concluded for all patients, Resverlogix anticipates being in a position to provide an updated projected timeframe for top-line data readout.

  • GlobeNewswire

    Resverlogix Announces Participation at Leading, International Scientific Conferences

    CALGARY, Alberta, June 10, 2019 -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at leading, international scientific.

  • GlobeNewswire

    Resverlogix Announces Closing of $15 Million Offering

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) is pleased to announce today that it has closed its previously announced offering (the “Offering”) of units of the Company (the “Units”). Each warrant is exercisable at a price of $4.60 per underlying common share for a period of 4 years from the closing of the Offering.

  • CNW Group

    IIROC Trade Resumption - RVX

    IIROC Trade Resumption - RVX

  • GlobeNewswire

    Resverlogix Announces Pricing of Unit Offering

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO)  is pleased to announce today that it has priced its previously announced marketed offering (the “Offering”) of units of the Company (the “Units”) at $4.00 per Unit.  Each Unit consists of one common share and one common share purchase warrant. Each warrant is exercisable at a price of $4.60 per underlying common share for a period of 4 years from the first closing of the Offering.

  • CNW Group

    IIROC Trading Halt - RVX

    IIROC Trading Halt - RVX

  • GlobeNewswire

    Resverlogix Announces Proposed Offering of Units

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) announced today that it has filed a preliminary short form prospectus with the securities regulatory authorities in  the  provinces of Ontario, Alberta and British Columbia in connection with a proposed marketed offering of units of the Company (“Units”), comprised of common shares and common share purchase warrants (the “Offering”). The number of Units to be distributed, the price and composition of each Unit, the minimum and maximum size of the Offering, and the exercise price and term of each warrant will be determined by negotiation between the Company and the Agent (as defined herein) in the context of the market.

  • GlobeNewswire

    Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) announced today the recent publication of an article titled: “Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension” in the high-impact, peer-reviewed medical journal, American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society. A Phase 2 clinical trial – studying apabetalone as a potential therapy for pulmonary arterial hypertension (PAH) – is expected to initiate following completion of an already planned pilot study to begin in the first half of 2019. “We are extremely pleased that our collaborative work resulted in this high-profile publication highlighting the potential of apabetalone and BET inhibition in the treatment of PAH and other diseases,” said Dr. Ewelina Kulikowski, Senior Vice President, Research & Development of the Company.

  • GlobeNewswire

    Resverlogix Announces 3-Month Loan Extension

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) today announces that it has entered into an amending agreement with Third Eye Capital (acting as agent for a syndicate of lenders) to extend the maturity date of the Company’s senior secured term loan by three months to August 4, 2019. In addition, the lenders agreed to reduce the minimum cash balance that the Company is required to maintain from US$5 million to US$3 million. Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor.

  • Zacks Small Cap Research

    RVX: 250 Events Reached!

    Resverlogix Corp. (RVX.TO) reported today that it has observed the targeted 250 events in its Phase III BETonMACE trial which began in November 2015. The study has a primary endpoint of time to first occurrence of Major Adverse Cardiac Event (MACE)1. The study will also examine kidney function in chronic kidney disease (CKD) patients as well as cognitive function in patients over 70 years of age.

  • GlobeNewswire

    Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) today announces that BETonMACE, the Company’s event-based, phase 3 registration trial has successfully reached 250 projected major adverse cardiac events (MACE), strictly defined as cardiovascular death, non-fatal myocardial infarction and stroke, moving the trial towards completion. Successful data from this trial would enable Resverlogix to proceed towards the regulatory approval and commercialization of its lead drug, apabetalone. “Resverlogix staff and stakeholders have worked diligently for the past 18 years to attain this extremely exciting goal,” said Donald McCaffrey, President and CEO of Resverlogix.